Abstract
We recently reported that variable expression of immune-response genes distinguishes tumor positive sentinel nodes in melanoma patients with malignant progression from those with non-progressing disease. Our results depict sentinel nodes as sites in which immune functions are associated with metastatic disease and identify CD30 as a host immune-related cancer prognostic marker and potential therapeutic target.
Original language | English |
---|---|
Article number | e28498 |
Journal | OncoImmunology |
Volume | 3 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- CD30
- Expression profiles
- Lymph node
- Melanoma
- Sentinel node
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology